Insiders Trades

★ Sign in to follow

AS

Andrew Schutte

RepliCel Life Sciences Inc.

Cumul. flow

Total declarations

13

Company

1

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

—

Latest filing published 05 Dec 2024 for RepliCel Life Sciences Inc..

Insider track record

Disclosed buys

0

Disclosed sells

0

Signal history

Andrew Schutte: trading record in brief

Andrew Schutte is a declared insider of RepliCel Life Sciences Inc., with filings sourced from SEDI. Over a trading history stretching from 14 December 2018 to 26 November 2024, the count stands at 13 filings.

No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

The record was last updated on 5 December 2024 with a transaction in RepliCel Life Sciences Inc. Filings reach the SEDI feed a median of 9 days after the trade. This delay matters because a trade only becomes useful information once it is public. Source: insider filings from SEDI. Past trades are no guide to future returns.

Companies and markets linked to Andrew Schutte

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

RepliCel Life Sciences Inc. (CA)

Declarations13 total

●

4 - Director of IssuerExecutives26 Nov 2024RepliCel Life Sciences Inc.

0SEDI

250,000 sharesConvertible Preferred Shares Class A Preference SharesTSXSEDI:4413162

●

4 - Director of IssuerExecutives26 Nov 2024RepliCel Life Sciences Inc.

0SEDI

1,968,611 sharesCommon SharesTSXSEDI:4413163

●

4 - Director of IssuerExecutives14 Mar 2023RepliCel Life Sciences Inc.

404,250 CAD20SEDI

4,042,500 shares@ CA$0.1047.0% of flowCommon SharesTSXSEDI:4095090

●

4 - Director of IssuerExecutives1 Feb 2023RepliCel Life Sciences Inc.

12,250 CAD13SEDI

116,666 shares@ CA$0.1051.5% of flowCommon SharesTSXSEDI:4070896

●

4 - Director of IssuerExecutives17 Jan 2023RepliCel Life Sciences Inc.

84,924 CAD12SEDI

943,596 shares@ CA$0.0910.0% of flowCommon SharesTSXSEDI:4065642

●

4 - Director of IssuerExecutives4 May 2022RepliCel Life Sciences Inc.

378,415 CAD18SEDI

2,102,303 shares@ CA$0.1828.1% of flowCommon SharesTSXSEDI:3951516

●

4 - Director of IssuerExecutives2 Jun 2021RepliCel Life Sciences Inc.

83,427 CAD15SEDI

216,693 shares@ CA$0.38523.4% of flowCommon SharesTSXSEDI:3758469

●

4 - Director of IssuerExecutives17 May 2021RepliCel Life Sciences Inc.

5,227 CAD11SEDI

29,037 shares@ CA$0.181.5% of flowCommon SharesTSXSEDI:3749654

●

4 - Director of IssuerExecutives18 Aug 2020RepliCel Life Sciences Inc.

128,645 CAD0SEDI

714,693 shares@ CA$0.18Common SharesTSXSEDI:3591639

●

4 - Director of IssuerExecutives15 Jul 2020RepliCel Life Sciences Inc.

202,590 CAD14SEDI

1,125,500 shares@ CA$0.1813.2% of flowCommon SharesTSXSEDI:3581788

●

4 - Director of IssuerExecutives4 Nov 2019RepliCel Life Sciences Inc.

166,870 CAD19SEDI

595,963 shares@ CA$0.2862.3% of flowCommon SharesTSXSEDI:3454378

●

4 - Director of IssuerExecutives14 Dec 2018RepliCel Life Sciences Inc.

0SEDI

Convertible Preferred Shares Class A Preference SharesTSXSEDI:3428520

●

4 - Director of IssuerExecutives10 Sept 2019RepliCel Life Sciences Inc.

100,000 CAD0SEDI

250,000 shares@ CA$0.4037.7% of flowConvertible Preferred Shares Class A Preference SharesTSXSEDI:3428521

13 of 13 declarations